Related Experiment Video
Updated: Jun 6, 2026

Generation of Tumor Organoids from Genetically Engineered Mouse Models of Prostate Cancer
Published on: June 13, 2019
Stem Cell-Derived Organoids for Cancer Therapy: Precision Medicine and Drug Selection
Md M N Azim1,2, Sujay Kumar Bhajan3, Jun Hong Park1
1Department of Physiology, College of Veterinary Medicine, Jeonbuk National University, Iksan 54596, Republic of Korea.
Abstract:
Millions of new cancer cases and deaths worldwide annually demonstrate the pressing need for predictive preclinical models that go beyond standard two-dimensional (2D) cultures and animal systems. Recent developments in three-dimensional (3D) organoid technology have yielded a powerful platform for generating patient-specific mini-organ models that faithfully recapitulate primary tumors at the genetic, phenotypic, and architectural levels. Organoids retain functional fidelity by preserving key stem cell signaling pathways, including Wnt, Notch, and Hippo, making them robust platforms for disease modeling and high-throughput drug screening. This review describes representative organoid systems, ranging from patient-derived organoids (PDOs) to induced pluripotent stem cell (iPSC)-derived organoids, that serve as disease-specific "avatars" for personalized therapeutics. Predictive accuracy rates greater than 90% have been shown in clinical studies, providing evidence for the relevance of organoids in functional precision medicine. In addition to drug discovery, the extended use of organoids in regenerative oncology can provide a unique regulatory mechanism by selectively targeting CSCs and enhancing tissue repair after cytotoxic treatments. Recent advances in organoid-on-a-chip platforms, 3D bioprinting, and artificial intelligence (AI) address critical challenges involving vascularization, immune system integration, and scalability. With the advent of standardized, GMP-compliant platforms and recent regulatory initiatives, such as the FDA Modernization Act 2.0, organoids are well-positioned to support next-generation cancer research and therapy. This review aims to bridge the gap between stem cell-derived organoids (SCDOs), providing a fully humanized platform for preclinical cancer modeling and their clinical application, and to discuss their potential to advance ethically guided, personalized cancer therapeutics with improved predictive and translational power.
Insights
Three-dimensional organoid technology creates patient-specific tumor models for precise cancer drug screening and personalized therapy. These advanced models show high predictive accuracy, paving the way for next-generation cancer research and treatment.
Area of Science:
- Biomedical Engineering
- Oncology
- Stem Cell Biology
Background:
- Cancer research urgently needs better preclinical models beyond 2D cultures and animal systems.
- Three-dimensional (3D) organoid technology offers patient-specific mini-organ models that mimic primary tumors.
- Organoids preserve key stem cell pathways (Wnt, Notch, Hippo) for disease modeling and drug screening.
Purpose of the Study:
- To review organoid systems, including patient-derived organoids (PDOs) and induced pluripotent stem cell (iPSC)-derived organoids, as 'avatars' for personalized cancer therapeutics.
- To highlight the role of organoids in functional precision medicine, citing >90% predictive accuracy in clinical studies.
- To discuss organoids' potential in regenerative oncology for targeting cancer stem cells (CSCs) and enhancing tissue repair.
Main Methods:
- Review of patient-derived organoids (PDOs) and induced pluripotent stem cell (iPSC)-derived organoids.
- Analysis of organoid applications in disease modeling, high-throughput drug screening, and regenerative oncology.
- Examination of advancements in organoid-on-a-chip, 3D bioprinting, and AI for addressing challenges like vascularization and immune integration.
Main Results:
- Organoids accurately recapitulate tumor genetics, phenotype, and architecture.
- Organoids demonstrate high predictive accuracy (>90%) in clinical studies, validating their use in precision medicine.
- Emerging technologies like organoid-on-a-chip and AI integration are enhancing organoid capabilities.
Conclusions:
- Organoids provide a fully humanized platform for preclinical cancer modeling and clinical applications.
- Organoid technology is poised to advance personalized cancer therapeutics with improved predictive and translational power.
- Standardized, GMP-compliant platforms and regulatory initiatives support the integration of organoids into cancer research and therapy.
More Related Videos
12:41Multiparametric Tumor Organoid Drug Screening Using Widefield Live-Cell Imaging for Bulk and Single-Organoid Analysis
Published on: December 23, 2022
07:31Author Spotlight: Establishment of Pancreatic Cancer-Derived Tumor Organoids and Fibroblasts From Fresh Tissue
Published on: May 26, 2023